---
title: "SL Science says FDA acknowledges orphan drug designation request for glioblastoma cell therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292318217.md"
description: "SL Science announced that the FDA's Office of Orphan Products Development acknowledged receipt of its orphan-drug designation request for Vdelta2+ gamma delta T-cell therapy in glioblastoma on March 30, 2026. This acknowledgment initiates the FDA's review of additional product files."
datetime: "2026-07-10T12:01:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292318217.md)
  - [en](https://longbridge.com/en/news/292318217.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292318217.md)
---

# SL Science says FDA acknowledges orphan drug designation request for glioblastoma cell therapy

-   SL Science submitted an FDA orphan-drug designation request for its Vdelta2+ gamma delta T-cell therapy in glioblastoma. \* FDA’s Office of Orphan Products Development acknowledged receipt on March 30, 2026, starting its review of additional product files. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SL Science Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100800PRIMZONEFULLFEED9760089) on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SLBT.US](https://longbridge.com/en/quote/SLBT.US.md)

## Related News & Research

- [SL Science Seeks FDA Orphan Drug Status for Gamma Delta T Cell Therapy in Glioblastoma](https://longbridge.com/en/news/292326758.md)
- [21:05 ETGalibra Neuroscience Receives FDA Orphan Drug and Rare Pediatric Disease Designations for SSADH Deficiency Gene Therapy](https://longbridge.com/en/news/295036462.md)
- [RARE: Record Q2 revenue and upcoming gene therapy launches position the company for 2027 profitability](https://longbridge.com/en/news/294883644.md)
- [Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020](https://longbridge.com/en/news/294966104.md)
- [IQVIA partners with Medera to advance cardiac gene therapy development](https://longbridge.com/en/news/294872007.md)